Zoetis Inc. (NYSE:ZTS) Shares Sold by Siemens Fonds Invest GmbH

Siemens Fonds Invest GmbH cut its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 12.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,687 shares of the company's stock after selling 2,192 shares during the period. Siemens Fonds Invest GmbH's holdings in Zoetis were worth $2,556,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Mission Wealth Management LP grew its stake in shares of Zoetis by 2.0% in the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. VeraBank N.A. grew its stake in shares of Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company's stock valued at $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC grew its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock valued at $224,000 after purchasing an additional 62 shares during the last quarter. Coppell Advisory Solutions LLC grew its stake in shares of Zoetis by 18.0% in the 4th quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after purchasing an additional 64 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company's stock valued at $170,000 after purchasing an additional 65 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.18% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on ZTS. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a report on Friday, February 14th. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, UBS Group decreased their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Price Performance

Shares of Zoetis stock traded up $1.57 on Friday, hitting $168.71. The company's stock had a trading volume of 5,467,815 shares, compared to its average volume of 2,533,285. The firm has a fifty day moving average price of $156.65 and a 200-day moving average price of $164.63. The company has a market capitalization of $75.11 billion, a P/E ratio of 30.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.38 earnings per share. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.19%. Zoetis's dividend payout ratio is presently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.